We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+12.8%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.21B
AUM Growth
-$296M
Cap. Flow
-$592M
Cap. Flow %
-18.42%
Top 10 Hldgs %
43.24%
Holding
304
New
89
Increased
36
Reduced
82
Closed
88

Top Buys

Rank Stock Value
1
ATAI icon
AtaiBeckley Inc
ATAI
+$25.3M
2
AGL icon
Agilon Health
AGL
+$13.5M
3
LLY icon
Eli Lilly
LLY
+$13.2M
4
PRVA icon
Privia Health
PRVA
+$12.8M
5
LNTH icon
Lantheus
LNTH
+$12.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$23.9M
2
VCEL icon
Vericel Corp
VCEL
+$20.8M
3
ALGN icon
Align Technology
ALGN
+$19M
4
SIBN icon
SI-BONE Inc
SIBN
+$17.5M
5
STAA icon
STAAR Surgical
STAA
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.64%
2 Industrials 1.41%
3 Materials 0.54%
4 Financials 0.48%
5 Consumer Staples 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
201
DELISTED
KalVista Pharmaceuticals
KALV
$478K 0.01%
19,956
-301
-1% -$7.88K
MAPSW
202
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$318K 0.01%
50,000
– –
RCUS icon
203
PUT
Arcus Biosciences
RCUS
$3.66B
$305K 0.01%
+11,100
New +$317K
ISEE
204
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$303K 0.01%
+48,065
New +$310K
LXRX icon
205
PUT
Lexicon Pharmaceuticals
LXRX
$1.08B
$291K 0.01%
+63,300
New +$305K
LPCN icon
206
CALL
Lipocine
LPCN
$17.2M
$280K 0.01%
+11,765
New +$277K
TCDA
207
DELISTED
Tricida, Inc. Common Stock
TCDA
$240K 0.01%
+55,620
New +$265K
FTH
208
Faeth Therapeutics
FTH
$773M
$208K 0.01%
1,130
-2,238
-66% -$553K
TCACU
209
DELISTED
Tuatara Capital Acquisition Corporation Unit
TCACU
$204K 0.01%
20,000
– –
SVRA icon
210
Savara
SVRA
$1.14B
$169K 0.01%
99,448
-552
-0.6% -$993
ACHV icon
211
Achieve Life Sciences
ACHV
$695M
$153K ﹤0.01%
+17,000
New +$162K
CHAQ.WS
212
DELISTED
Chardan Healthcare Acquisition 2 Corp. Warrants, entitling the holder thereof to purchase one-half (
CHAQ.WS
$99K ﹤0.01%
153,960
– –
LPCN icon
213
Lipocine
LPCN
$17.2M
$77K ﹤0.01%
+3,220
New +$75.7K
HURA
214
TuHURA Biosciences
HURA
$146M
$64K ﹤0.01%
+16
New +$46K
ABCL icon
215
AbCellera Biologics
ABCL
$2.99B
– –
-225,000
Closed -$7.64M
ABT icon
216
PUT
Abbott
ABT
$190B
– –
-150,000
Closed -$18M
ACAD icon
217
PUT
Acadia Pharmaceuticals
ACAD
$5.07B
– –
-100,000
Closed -$2.58M
ACRS icon
218
Aclaris Therapeutics
ACRS
$871M
– –
-175,799
Closed -$4.43M
AFMD
219
DELISTED
Affimed
AFMD
– –
-24,054
Closed -$1.9M
ALGN icon
220
Align Technology
ALGN
$12.3B
– –
-35,000
Closed -$19M
AMWL icon
221
PUT
American Well
AMWL
$221M
– –
-5,000
Closed -$1.74M
ATRC icon
222
CALL
AtriCure
ATRC
$2.18B
– –
-49,800
Closed -$3.26M
AUPH icon
223
Aurinia Pharmaceuticals
AUPH
$2.04B
– –
-50,575
Closed -$657K
BCAB icon
224
BioAtla
BCAB
$5.81M
– –
-180
Closed -$457K
BFLY icon
225
Butterfly Network
BFLY
$2.5B
– –
-183,765
Closed -$3.09M
7 8
9
10 11

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2021 Portfolio in Review

As of Q2 2021, Pura Vida Investments held 304 positions worth $3.21B, down 8.4% from $3.51B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Pura Vida Investments withdrew a net $592M in Q2 2021, closing 88 positions and reducing 82 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $23.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.

Against the trend, Pura Vida Investments opened a new position in AtaiBeckley Inc worth $23.2M.

  • Pura Vida Investments's largest Q2 2021 buy was AtaiBeckley Inc: 1,371,824 shares worth $23.2M.
  • Pura Vida Investments added most to Quotient Limited Ordinary Shares in Q2 2021, an estimated $9.15M increase.
  • Pura Vida Investments's biggest Q2 2021 reduction was STAAR Surgical, cutting an estimated $14.6M.
  • Pura Vida Investments fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $23.9M.
  • Pura Vida Investments's ten largest holdings make up 43% of its $3.21B portfolio in Q2 2021.
  • Pura Vida Investments opened 89 new positions and closed 88 in Q2 2021.
  • Pura Vida Investments's portfolio value fell 8.4% quarter-over-quarter to $3.21B.

Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.